MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03339cam a2200325 a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
EG-GiCUC |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
211219s2021 ua dh f m 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
EG-GiCUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GiCUC |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| 049 ## - LOCAL HOLDINGS (OCLC) |
|---|
| Holding library |
Deposite |
| 097 ## - Thesis Degree |
|---|
| Thesis Level |
Ph.D |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Classification number |
Cai01.11.33.Ph.D.2021.Na.E |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Naeema Mohamed Ahmed Gad |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Evaluation of renal function changes during sofosburvir and daclatasvir (+/- ribavirin) treatment in chronic HCV monoinfected patients compared to HCV/HIV co-infected patients / |
| Statement of responsibility, etc. |
Naeema Mohamed Ahmed Gad ; Supervised Mohammad Salah Abdelbary , Shereen Abdalem Mohamed , Engy Mohamed Elkhateeb |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
تقييم تغيرات وظائف الكلى أثناء علاج فيروس سى( سوفوسبوفير و داكلاتسفير +/- ريبافيرين) بمرضى الالتهاب الكبدى المزمن بفيروس سى مقارنة بمرضى العدوى المشتركه بفيروس نقص المناعه البشريه والتهاب الكبدى المزمن بفيروس سى |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
Cairo : |
| Name of publisher, distributor, etc. |
Naeema Mohamed Ahmed Gad , |
| Date of publication, distribution, etc. |
2021 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
142 P. : |
| Other physical details |
charts , facsimiles ; |
| Dimensions |
25cm |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Background: Hepatitis C virus (HCV) infection among people living with human immunodeficiency virus (PLHI) is a growing worldwide health burden. Sofosbuvir is approved for HCV patients.The nephrotoxicity of SOF on HCV mono-infected and HCV/HIV patients receiving antiretroviral therapy (ART) remains controversial. Aim: to evaluatethe serial changes of renal indices during sofosbuvir (SOF) and daclatasvir (DCV) therapy in HCV mono-infected and HCV/HIV patients with normal to mildly impaired kidney functions. Patients and methods: A prospective study including 159 HCV mono-infected and 124 HCV/HIV patients (47 were ART-naïve and 77 were TDF-based cART) who presented with a baseline eGFR {u2265}60 ml/min/1.73m² and were treated with SOF/DCV for 12 weeks.The eGFR was calculated for each time of evaluation using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.Results: HCV patients had a progressive eGFR decline compared to HCV/HIV patients who were ART-naive and those receiving TDF-based cART during and after discontinuing SOF/DAC treatment (95.5, 108.7,109.2 ml/min/1.73m² at baseline vs. 93.4, 113.8, 106.4 ml/min/1.73m² at EOT vs. 92.91, 113.8, 111.9 ml/min/1.73m² at SVR12, respectively). However, the rate of eGFR stage improvement was more pronounced in HCV mono-infected compared to HCV/HIV patients who were ART-naive and those receiving TDF-based ART at EOT and SVR12 (13.8% vs. 8.5% and 6.5% at EOTand 14.5% vs. 12.7% and 10.4% at SVR12, respectively).Multivariable regression analysis showed that baseline variables were not independent predictors of eGFR stage worsening either at EOT or SVR12 |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Additional physical form available note |
Issued also as CD |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Estimated Glomerular Filtration Rate |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Hepatitis C Virus |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Human Immunodeficiency Virus |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Engy Mohamed Elkhateeb , |
| Relator term |
|
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Mohammad Salah Abdelbary , |
| Relator term |
|
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Shereen Abdalem Mohamed , |
| Relator term |
|
| 905 ## - LOCAL DATA ELEMENT E, LDE (RLIN) |
|---|
| Cataloger |
Nazla |
| Reviser |
Revisor |
| 905 ## - LOCAL DATA ELEMENT E, LDE (RLIN) |
|---|
| Cataloger |
Shimaa |
| Reviser |
Cataloger |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
